CPASMA: Is There an Improvement in Asthma in Patients With Both Asthma and OSAS Treated With CPAP?

The CPASMA Trial: Is There an Improvement in Asthma in Patients With Both Asthma and Obstructive Sleep Apnoea Syndrome (OSAS) Treated With Continuous Positive Airway Pressure (CPAP) After Six Months?

Status

UNKNOWN

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01374932

Acronym

CPASMA

Enrollment

120

Registered

2011-06-16

Start date

2011-07-31

Completion date

2013-12-31

Last updated

2012-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asthma, Obstructive Sleep Apnea Syndrome

Keywords

Asthma, Obstructive Sleep Apnea Syndrome

Brief summary

The CPASMA trial is a descriptive, prospective, multicentre clinical trial, with a before/after Continuous Positive Airway Pressure (CPAP) assessment in participating patients. It aims to answer the following question: Is there an improvement in asthma in those patients with both asthma and obstructive sleep apnoea syndrome (OSAS) treated with CPAP after six months?. It is hypothesized that treatment of OSAS with CPAP in patients with both OSAS and asthma concommitantly, may have a beneficial effect also on asthma outcomes. This clinical effect in asthma could be assessed objectively by applying validated questionnaires for quality of life and asthma control.

Detailed description

Full protocol in Spanish, available upon request

Interventions

DEVICECPAP

Continuous positive airways pressure (CPAP)

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 70 Years

Healthy volunteers

Inclusion criteria

* Adult patients (18 to 70 yrs.) with asthma who require treatment with CPAP because of OSAS (RDI\> = 20 events per hour)

Exclusion criteria

* unstable or severe comorbidity, * patients in treatment with drugs that interfere with the clinical course of asthma and/or OSAS, * cognitive/psychiatric disorders that preclude patient participation/cooperation, * COPD or other lung disease accompanied by chronic airflow limitation, and * any clinical condition considered severe enough by the investigators to preclude all the diagnostic and therapeutic procedures outlined in this protocol.

Design outcomes

Primary

Measure	Time frame	Description
Asthma control questionnaire	6 months	Changes in clinical and functional variables and in the asthma control questionnaire (ACQ) in the period prior to start the CPAP treatment and after a 6-months follow-up period

Countries

Spain

Contacts

Primary ContactJosé Serrano, MD

jserrano@separ.es+34-971888500

Backup ContactJoan B Soriano, MD

jbsoriano@caubet-cimera.es

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026